Literature DB >> 8692823

A point mutation in the HIV-1 Tat responsive element is associated with postintegration latency.

S Emiliani1, C Van Lint, W Fischle, P Paras, M Ott, J Brady, E Verdin.   

Abstract

Study of the mechanism of HIV-1 postintegration latency in the ACH2 cell line demonstrates that these cells failed to increase HIV-1 production following treatment with exogenous Tat. Reasoning that the defect in ACH2 cells involves the Tat response, we analyzed the sequence of tat cDNA and Tat responsive element (TAR) from the virus integrated in ACH2. Tat cDNA sequence is closely related to that of HIV LAI, and the encoded protein is fully functional in terms of long terminal repeat (LTR) transactivation. Cloning of a region corresponding to the 5'-LTR from ACH2, however, identified a point mutation (C37 -> T) in TAR. This mutation impaired Tat responsiveness of the LTR in transient transfection assays, and the measured defect was complemented in cells that had been treated with tetradecanoyl phorbol acetate or tumor necrosis factor type alpha (TNF-alpha). A compensatory mutation in TAR (G28 -> A), designed to reestablish base pairing in the TAR hairpin, restored wild-type Tat responsiveness. When the (C37 -> T) mutation was introduced in an infectious clone of HIV-1, no viral production was measured in the absence of TNF-alpha, whereas full complementation was observed when the infection was conducted in the presence of TNF-alpha or when a compensatory mutation (G28 -> A) was introduced into TAR. These experiments identify a novel mutation associated with HIV-1 latency and suggest that alterations in the Tat-TAR axis can be a crucial determinant of the latent phenotype in infected individuals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8692823      PMCID: PMC39030          DOI: 10.1073/pnas.93.13.6377

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  Cellular latency of human immunodeficiency virus type 1.

Authors:  R J Pomerantz; O Bagasra; D Baltimore
Journal:  Curr Opin Immunol       Date:  1992-08       Impact factor: 7.486

2.  Electroporation of viral transactivator proteins into lymphocyte suspension cells.

Authors:  F Kashanchi; J F Duvall; J N Brady
Journal:  Nucleic Acids Res       Date:  1992-09-11       Impact factor: 16.971

3.  Two distinct nuclear transcription factors recognize loop and bulge residues of the HIV-1 TAR RNA hairpin.

Authors:  C T Sheline; L H Milocco; K A Jones
Journal:  Genes Dev       Date:  1991-12       Impact factor: 11.361

4.  HIV-1 latency due to the site of proviral integration.

Authors:  B J Winslow; R J Pomerantz; O Bagasra; D Trono
Journal:  Virology       Date:  1993-10       Impact factor: 3.616

5.  Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in situ hybridization and flow cytometry.

Authors:  B K Patterson; M Till; P Otto; C Goolsby; M R Furtado; L J McBride; S M Wolinsky
Journal:  Science       Date:  1993-05-14       Impact factor: 47.728

6.  Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses.

Authors:  B K Chen; K Saksela; R Andino; D Baltimore
Journal:  J Virol       Date:  1994-02       Impact factor: 5.103

7.  Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS.

Authors:  J Embretson; M Zupancic; J L Ribas; A Burke; P Racz; K Tenner-Racz; A T Haase
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

8.  HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease.

Authors:  G Pantaleo; C Graziosi; J F Demarest; L Butini; M Montroni; C H Fox; J M Orenstein; D P Kotler; A S Fauci
Journal:  Nature       Date:  1993-03-25       Impact factor: 49.962

9.  DNase I-hypersensitive sites are associated with both long terminal repeats and with the intragenic enhancer of integrated human immunodeficiency virus type 1.

Authors:  E Verdin
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  Chromatin disruption in the promoter of human immunodeficiency virus type 1 during transcriptional activation.

Authors:  E Verdin; P Paras; C Van Lint
Journal:  EMBO J       Date:  1993-08       Impact factor: 11.598

View more
  84 in total

1.  Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain.

Authors:  Alexander Dorr; Veronique Kiermer; Angelika Pedal; Hans-Richard Rackwitz; Peter Henklein; Ulrich Schubert; Ming-Ming Zhou; Eric Verdin; Melanie Ott
Journal:  EMBO J       Date:  2002-06-03       Impact factor: 11.598

2.  Identification of T cell-signaling pathways that stimulate latent HIV in primary cells.

Authors:  David G Brooks; Philip A Arlen; Lianying Gao; Christina M R Kitchen; Jerome A Zack
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-20       Impact factor: 11.205

Review 3.  Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells.

Authors:  Alberto Bosque; Vicente Planelles
Journal:  Methods       Date:  2010-10-21       Impact factor: 3.608

4.  A doxycycline-dependent human immunodeficiency virus type 1 replicates in vivo without inducing CD4+ T-cell depletion.

Authors:  Nicolas Legrand; Gisela J van der Velden; Raphaël Ho Tsong Fang; Marc Douaisi; Kees Weijer; Atze T Das; Bianca Blom; Christel H Uittenbogaart; Ben Berkhout; Mireille Centlivre
Journal:  J Gen Virol       Date:  2012-05-30       Impact factor: 3.891

Review 5.  Molecular mechanisms of HIV latency.

Authors:  Daniele C Cary; Koh Fujinaga; B Matija Peterlin
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

6.  Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency.

Authors:  Olaf Kutsch; Etty N Benveniste; George M Shaw; David N Levy
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Primary cell model for activation-inducible human immunodeficiency virus.

Authors:  Bryan Burke; Helen J Brown; Matthew D Marsden; Gregory Bristol; Dimitrios N Vatakis; Jerome A Zack
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

8.  Poly(ADP-ribose) polymerase 1 promotes transcriptional repression of integrated retroviruses.

Authors:  Murilo T D Bueno; Daniel Reyes; Luis Valdes; Adarsh Saheba; Eduardo Urias; Crystal Mendoza; Oliver I Fregoso; Manuel Llano
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

9.  15-Deoxy-Delta12,14-prostaglandin J2 inhibits HIV-1 transactivating protein, Tat, through covalent modification.

Authors:  Parisa Kalantari; Vivek Narayan; Andrew J Henderson; K Sandeep Prabhu
Journal:  FASEB J       Date:  2009-03-19       Impact factor: 5.191

Review 10.  Cellular reservoirs of HIV-1 and their role in viral persistence.

Authors:  Aikaterini Alexaki; Yujie Liu; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2008-09       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.